Black Diamond Therapeutics Files Q1 2025 10-Q
Ticker: BDTX · Form: 10-Q · Filed: May 12, 2025 · CIK: 1701541
| Field | Detail |
|---|---|
| Company | Black Diamond Therapeutics, Inc. (BDTX) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
BDTX filed Q1 10-Q. Financials for period ending 3/31/25.
AI Summary
Black Diamond Therapeutics, Inc. filed its Q1 2025 10-Q on May 12, 2025, reporting financial results for the period ending March 31, 2025. The company, formerly Aset Therapeutics, Inc., is focused on biological products. Specific financial figures and operational details for this quarter are not detailed in the provided header information.
Why It Matters
This filing provides an update on Black Diamond Therapeutics' financial health and operational status for the first quarter of 2025, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Black Diamond Therapeutics operates in a high-risk, high-reward industry with significant research and development expenses and regulatory hurdles.
Key Numbers
- Q1 2025 — Reporting Period (Financial results for the first quarter of 2025.)
- 001-39200 — SEC File Number (Identifier for Black Diamond Therapeutics' SEC filings.)
Key Players & Entities
- Black Diamond Therapeutics, Inc. (company) — Filer of the 10-Q
- Aset Therapeutics, Inc. (company) — Former name of Black Diamond Therapeutics
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date of the 10-Q
FAQ
What is the primary business of Black Diamond Therapeutics, Inc.?
Black Diamond Therapeutics, Inc. is primarily involved in the biological products sector, specifically classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on May 12, 2025.
What period does this 10-Q report cover?
This 10-Q report covers the period ending March 31, 2025 (Q1 2025).
What was the former name of Black Diamond Therapeutics, Inc.?
The former name of Black Diamond Therapeutics, Inc. was Aset Therapeutics, Inc., with a date of name change on March 21, 2017.
Where is Black Diamond Therapeutics, Inc. located?
Black Diamond Therapeutics, Inc. is located at One Main Street, 14th Floor, Cambridge, MA 02142.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Black Diamond Therapeutics, Inc. (BDTX).